Nextel Medical Corp. (MAJI) Fair Value 2026

MAJI · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.9 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-27, Nextel Medical Corp. (MAJI) trades at $0.01. QOC: 2.9/10. Value Trap Risk: 0/100 (SAFE). 1/13 models active.

Key Facts

Ticker
MAJI
Price
$0.01
Quality Score
2.9/10
Value Trap Risk
0/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +62.5% upside with 4% confidence
Risk: Below-average Quality Score of 2.9/10 signals weak fundamentals

What Fair Value Does Each Model Give MAJI?

1 Intrinsic Value Models vs. Current Price ($0.01)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Low Conviction
 $0.01 +62.5%

All Models Active

All 1 models are displayed above.

What Is Nextel Medical Corp. (MAJI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Nextel Medical Corp.'s intrinsic value is estimated at a median fair value of $0.01. At a current market price of $0.01, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +62.5%.

What Do the Models Say About MAJI?

1 of 13 models are currently active for MAJI. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does MAJI Rank in Biotechnology?

Among 620 Biotechnology stocks, MAJI ranks #595 by Quality of Company score. CirclFi's QOC score of 2.9/10 evaluates 32 fundamental signals. A score of 2.9 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Nextel Medical Corp. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating MAJI should weigh these sector-specific dynamics alongside our model-derived fair values.

Is MAJI a Value Trap?

CirclFi's Value Trap algorithm assigns MAJI a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Nextel Medical Corp.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Nextel Medical Corp.'s fundamental quality profile registers 2.9/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MAJI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MAJI's 1 active models, average confidence is 4%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Nextel Medical Corp. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ARGXargenx SEQOC 2.9YDESYD Bio LtdQOC 2.8WINTWindtree Therapeutics, Inc.QOC 3.0DRTSAlpha Tau Medical Ltd.QOC 2.6MENSJyong Biotech Ltd.QOC 3.0PHARPharming Group N.V.QOC 2.6DTILPrecision BioSciences, Inc.QOC 6.2MCRBSeres Therapeutics, Inc.QOC 5.1EDSAEdesa Biotech, Inc.QOC 4.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ARGX · YDES · WINT · DRTS · MENS · PHAR · DTIL · MCRB · EDSA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to MAJI?

7 companies across all industries closest to MAJI’s Quality of Company score of 2.9/10.

AMLMAmerican Lithium Minerals, Inc.QOC 2.9BFCHBitFrontier Capital Holdings, Inc.QOC 2.9ACRLAtacama Resources International, Inc.QOC 2.9AHMAAmbitions Enterprise Management Co. L.L.CQOC 2.9AEMAgnico Eagle Mines LimitedQOC 2.9SNTSenstar Technologies CorporationQOC 2.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AMLM · BFCH · ACRL · AHMA · AEM · SNT · NVDA

Where Does MAJI Sit in CirclFi's Biotechnology Rankings?

MAJI is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Nextel Medical Corp.’s Valuation?

What is Nextel Medical Corp.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Nextel Medical Corp. (MAJI). The Quality of Company score is 2.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MAJI overvalued or undervalued right now?

At $0.01, 1 of 1 active models suggest MAJI may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Nextel Medical Corp.'s business model in Biotechnology.

What does a Quality of Company score of 2.9 mean for MAJI?

Nextel Medical Corp.'s QOC of 2.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on MAJI?

CirclFi analyzes MAJI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is MAJI a value trap in 2026?

Nextel Medical Corp.'s Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Nextel Medical Corp. (MAJI) a Quality of Company score of 2.9/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/MAJI/ · Methodology
Primary sources for this MAJI valuation
  • Financial statements: Nextel Medical Corp. 10-K and 10-Q filings on SEC EDGAR (CIK 0001492448) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MAJI as of ; valuations recomputed .